Sudipto Mukherjee graduated with a MBBS degree in Medicine from the Nil Ratan Sircar Medical College and Hospital, India, and went on to obtain a Master’s in Public Health and a PhD in Vision Sciences from the University of Alabama at Birmingham, US. After his graduate studies, he undertook his residency in Internal Medicine at William Beaumont Hospital, Oakland University, MI. He completed a fellowship in hematology and medical oncology at the Cleveland Clinic. He is currently appointed as an Assistant Professor in Internal Medicine at the Lerner College of Medicine at Case Western Reserve University. Since 2020, he has been the Director of the Rare Cancers and Blood Diseases Program at the Cleveland Clinic Taussig Cancer Institute. As part of the Rare Cancers and Blood Diseases Program, he leads a multidisciplinary specialty team that provides clinical care and conducts research across a wide spectrum of rare diseases that now encompasses 84 conditions.
As part of his clinical responsibilities he manages patients with myeloid malignancies and several rare blood conditions particularly Castleman disease, histiocytic disorders, systemic mastocytosis among others. His research interests are on conducting large population-level epidemiological analyses of second cancer risk in cancer survivors, racial/ethnic disparities in health outcomes and clinical trials. He currently leads several investigator-initiated non-therapeutic as well as therapeutic clinical trials in AML, MDS, CML, histiocytic disorders and systemic mastocytosis. He is a member of the Castleman Disease Collaborative Network (CDCN) and serves on the CDCN Scientific Advisory Board. He has been an active participant in the development of the international guidelines for the management of idiopathic multicentric Castleman disease.